Assembly Biosciences, Inc. (ASMB): Price and Financial Metrics

Assembly Biosciences, Inc. (ASMB): $1.31

0.01 (+0.77%)

POWR Rating

Component Grades














  • Growth is the dimension where ASMB ranks best; there it ranks ahead of 59.43% of US stocks.
  • The strongest trend for ASMB is in Stability, which has been heading up over the past 179 days.
  • ASMB ranks lowest in Momentum; there it ranks in the 3rd percentile.

ASMB Stock Summary

  • Of note is the ratio of ASSEMBLY BIOSCIENCES INC's sales and general administrative expense to its total operating expenses; just 7.73% of US stocks have a lower such ratio.
  • The ratio of debt to operating expenses for ASSEMBLY BIOSCIENCES INC is higher than it is for about just 9.15% of US stocks.
  • Revenue growth over the past 12 months for ASSEMBLY BIOSCIENCES INC comes in at -82.46%, a number that bests only 1.57% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to ASMB, based on their financial statements, market capitalization, and price volatility, are PULM, SLS, APVO, MIRO, and ZLAB.
  • Visit ASMB's SEC page to see the company's official filings. To visit the company's web site, go to

ASMB Valuation Summary

  • ASMB's EV/EBIT ratio is -0.3; this is 103.95% lower than that of the median Healthcare stock.
  • ASMB's price/earnings ratio has moved up 2.5 over the prior 144 months.

Below are key valuation metrics over time for ASMB.

Stock Date P/S P/B P/E EV/EBIT
ASMB 2022-11-01 12.8 0.6 -0.6 -0.3
ASMB 2022-10-31 12.7 0.6 -0.6 -0.3
ASMB 2022-10-28 12.8 0.6 -0.6 -0.3
ASMB 2022-10-27 12.7 0.6 -0.6 -0.3
ASMB 2022-10-26 13.0 0.7 -0.6 -0.3
ASMB 2022-10-25 12.5 0.6 -0.6 -0.3

ASMB Growth Metrics

    Its year over year net cashflow from operations growth rate is now at -23.17%.
  • Its year over year net income to common stockholders growth rate is now at -100.56%.
  • The 2 year net cashflow from operations growth rate now stands at -2.59%.
Over the past 67 months, ASMB's revenue has gone up $6,254,000.

The table below shows ASMB's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 6.254 -83.631 -126.612
2022-03-31 6.254 -87.554 -125.746
2021-12-31 6.254 -93.396 -129.855
2021-09-30 7.291 -99.303 -109.016
2021-06-30 35.648 -69.775 -93.562
2021-03-31 75.024 -71.083 -62.697

ASMB's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ASMB has a Quality Grade of D, ranking ahead of 6.92% of graded US stocks.
  • ASMB's asset turnover comes in at 0.126 -- ranking 245th of 682 Pharmaceutical Products stocks.
  • NERV, BLUE, and GTHX are the stocks whose asset turnover ratios are most correlated with ASMB.

The table below shows ASMB's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.126 1 -0.553
2021-03-31 0.258 1 -0.373
2020-12-31 0.264 1 -0.337
2020-09-30 0.264 1 -0.250
2020-06-30 0.179 1 -0.381
2020-03-31 0.058 1 -0.512

ASMB Price Target

For more insight on analysts targets of ASMB, see our ASMB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $9.71 Average Broker Recommendation 1.71 (Moderate Buy)

ASMB Stock Price Chart Interactive Chart >

Price chart for ASMB

ASMB Price/Volume Stats

Current price $1.31 52-week high $2.45
Prev. close $1.30 52-week low $1.20
Day low $1.27 Volume 165,900
Day high $1.35 Avg. volume 401,294
50-day MA $1.53 Dividend yield N/A
200-day MA $1.83 Market Cap 63.90M

Assembly Biosciences, Inc. (ASMB) Company Bio

Assembly Biosciences develops oral therapies for intractable infectious diseases in the United States. The company focuses on the hepatitis B virus and C. difficile-associated infections. The company was founded in 2005 and is based in New York, New York.

ASMB Latest News Stream

Event/Time News Detail
Loading, please wait...

ASMB Latest Social Stream

Loading social stream, please wait...

View Full ASMB Social Stream

Latest ASMB News From Around the Web

Below are the latest news stories about ASSEMBLY BIOSCIENCES INC that investors may wish to consider to help them evaluate ASMB as an investment opportunity.

Assembly Biosciences Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334

Healthy volunteer study will inform development of 4334 for treatment of hepatitis B virus SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced that the first subject has been dosed in the Phase 1a trial of its investigational core inhibitor ABI-4334 (4334). 4334 is an investigat

Yahoo | November 14, 2022

Analysts Offer Insights on Healthcare Companies: Emergent Biosolutions (EBS), Inovio Pharmaceuticals (INO) and Assembly Biosciences (ASMB)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Emergent Biosolutions (EBS – Research Report), Inovio Pharmaceuticals (INO – Research Report) and Assembly Biosciences (ASMB – Research Report). Emergent Biosolutions (EBS) Chardan Capital analyst Keay Nakae reiterated a Buy rating on Emergent Biosolutions today and set a price target of $55.00. The company's shares closed last Tuesday at $19.73, close to its 52-week low of $18.00. According to TipRanks.

Howard Kim on TipRanks | November 9, 2022

After Plunging 17% in 4 Weeks, Here's Why the Trend Might Reverse for Assembly Biosciences (ASMB)

The heavy selling pressure might have exhausted for Assembly Biosciences (ASMB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Yahoo | November 9, 2022

Assembly Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights and Announces Upcoming Conference Participation

Phase 1a Trial of Next-Generation Core Inhibitor, ABI-4334, Now Underway Following Clinical Trial Application (CTA) Clearance SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced financial results and recent highlights for the third quarter ended September 30, 2022. “During the t

Yahoo | November 8, 2022

Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV

Data demonstrating nanomolar potency of core inhibitor ABI-4334 to disrupt the hepatitis B virus (HBV) life cycle at multiple points supports advancement into clinical studies First data presented on preclinical characterization of potent, orally bioavailable viral entry inhibitors for HBV and hepatitis D virus (HDV) First data presented on novel series of orally bioavailable small molecule interferon-a receptor (IFNAR) agonists designed to inhibit HBV and engage the immune system with potential

Yahoo | November 4, 2022

Read More 'ASMB' Stories Here

ASMB Price Returns

1-mo -13.82%
3-mo N/A
6-mo -37.91%
1-year -38.50%
3-year -91.81%
5-year -97.03%
YTD -43.78%
2021 -61.49%
2020 -70.43%
2019 -9.55%
2018 -50.01%
2017 272.43%

Continue Researching ASMB

Want to see what other sources are saying about Assembly Biosciences Inc's financials and stock price? Try the links below:

Assembly Biosciences Inc (ASMB) Stock Price | Nasdaq
Assembly Biosciences Inc (ASMB) Stock Quote, History and News - Yahoo Finance
Assembly Biosciences Inc (ASMB) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9737 seconds.